Mylan generic schizophrenia drug infringes Janssen patent, US appeals court says
Mylan Laboratories’ generic version of Janssen Pharmaceuticals’s schizophrenia medication Invega Trinza is likely to infringe a Janssen patent, the US Court of Appeals for the Federal Circuit affirmed Friday in a...To view the full article, register now.
Already a subscriber? Click here to view full article